Actavis predicts bumper fourth quarter as it reorganizes after Chilcott buy
This article was originally published in Scrip
Actavis's "exceptional" performance during a "transformational" 2013 will result in a fourth quarter EPS modestly above the high end of its previous forecast, said the company. A full business update will be provided at its investor day on 31 January, ahead of reporting final results for the fourth quarter and full year 2013 on 20 February.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.